Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs

This review evaluates drug delivery systems that involve intact plasma lipoproteins or some of their components. These complex macromolecules transport highly water-insoluble compounds (cholesteryl esters and triacylglycerols) in their natural environment – a property that renders them ideal carriers of hydrophobic drugs. Particular emphasis is placed on the application of lipoproteins as drug delivery agents in cancer chemotherapy. The history and present activity regarding lipoprotein-based formulations are reviewed, with the primary focus on the smaller sized (low and high density) lipoprotein-based formulations and their potential clinical and commercial value. The use of both native and synthetic lipoproteins as drug delivery agents are discussed from the standpoint of therapeutic efficacy, as well as commercial feasibility. The advantages of lipoprotein-based drug delivery formulations are compared with other drug delivery models, with the primary focus on liposomal preparations. Finally, an expert opinion is provided, regarding the potential use of lipoprotein-based formulations in cancer treatment, taking into consideration the major advantages (biocompatibility, safety, drug solubility) and the barriers (manufacturing protein components, financial interest, investments) to their commercial development.

[1]  V. Torchilin.  Fluorescence microscopy to follow the targeting of liposomes and micelles to cells and their intracellular fate. , 2005, Advanced drug delivery reviews.

[2]  D. Atkinson,et al.  [33] Reassembly of low-density lipoproteins , 1986 .

[3]  T. V. van Berkel,et al.  LDL-mediated drug targeting. , 1990, Critical reviews in therapeutic drug carrier systems.

[4]  S. Vitols,et al.  Low Density Lipoprotein as a Carrier of Cytostatics in Cancer Chemotherapy: Study of Stability of Drug-carrier Complexes in Blood , 2000, Journal of drug targeting.

[5]  P. Linsel-Nitschke,et al.  HDL as a target in the treatment of atherosclerotic cardiovascular disease , 2005, Nature Reviews Drug Discovery.

[6]  A. Lacko,et al.  High density lipoprotein complexes as delivery vehicles for anticancer drugs. , 2002, Anticancer research.

[7]  P. Palatini.  Disposition kinetics of phospholipid liposomes. , 1992, Advances in experimental medicine and biology.

[8]  L. Pagano,et al.  Return to normal values of lipid pattern after effective chemotherapy in acute lymphoblastic leukemia. , 1996, Haematologica.

[9]  H. Adlercreutz,et al.  Antiproliferative efficacy of lipophilic soy isoflavone phytoestrogens delivered by low density lipoprotein particles into cultured U937 cells. , 1999, Life sciences.

[10]  B. Lundberg.  A Submicron Lipid Emulsion Coated with Amphipathic Polyethylene Glycol for Parenteral Administration of Paclitaxel (Taxol) , 1997, The Journal of pharmacy and pharmacology.

[11]  M. Brown,et al.  Inefficient internalization of receptor-bound low density lipoprotein in human carcinoma A-431 cells , 1981, The Journal of cell biology.

[12]  M. Dellian,et al.  Neovascular targeting chemotherapy: Encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature , 2004, International journal of cancer.

[13]  E. Simpson,et al.  Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. , 1981, American journal of obstetrics and gynecology.

[14]  A. Jonas,et al.  Apolipoprotein A-I structure and lipid properties in homogeneous, reconstituted spherical and discoidal high density lipoproteins. , 1990, The Journal of biological chemistry.

[15]  A. Lacko,et al.  Trojan Horse Meets Magic Bullet to Spawn a Novel, Highly Effective Drug Delivery Model , 2006, Chemotherapy.

[16]  G. Gahrton,et al.  Significance of the low-density lipoprotein (LDL) receptor pathway for the in vitro accumulation of AD-32 incorporated into LDL in normal and leukemic white blood cells. , 1984, Cancer treatment reports.

[17]  D. Sparks,et al.  The conformation of apolipoprotein A-I in discoidal and spherical recombinant high density lipoprotein particles. 13C NMR studies of lysine ionization behavior. , 1992, The Journal of biological chemistry.

[18]  R. Hovorka,et al.  Mass kinetics of apolipoprotein A-I in interstitial fluid after administration of intravenous apolipoprotein A-I/lecithin discs in humans , 2006, Journal of Lipid Research.

[19]  Minghan Wang,et al.  HDL: The Metabolism, Function, and Therapeutic Importance , 2004 .

[20]  A. Miyauchi,et al.  Evidence for a potential role for HDL as an important source of cholesterol in human adrenocortical tumors via the CLA-1 pathway. , 1999, Endocrine journal.

[21]  S. Baker,et al.  Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  A. Rigotti,et al.  Getting a handle on "good" cholesterol with the high-density lipoprotein receptor. , 1999, The New England journal of medicine.

[23]  R. Schiffelers,et al.  Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. , 1997, Molecular pharmacology.

[24]  S. Feng,et al.  A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[25]  D. Lesieur,et al.  Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. , 1992, Cancer research.

[26]  G. Gahrton,et al.  Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Krieger,et al.  Replacement of endogenous cholesteryl esters of low density lipoprotein with exogenous cholesteryl linoleate. Reconstitution of a biologically active lipoprotein particle. , 1978, The Journal of biological chemistry.

[28]  D. Steinberg,et al.  Characterization of CLA-1, a Human Homologue of Rodent Scavenger Receptor BI, as a Receptor for High Density Lipoprotein and Apoptotic Thymocytes* , 1997, The Journal of Biological Chemistry.

[29]  A. Sumner,et al.  The physiology of lipoproteins , 2002, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[30]  J. Schellens,et al.  Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes , 2001, Investigational New Drugs.

[31]  J. E. Doran,et al.  Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia , 1996, The Journal of experimental medicine.

[32]  B. Karten,et al.  The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. , 2000, The Biochemical journal.

[33]  R. Counsell,et al.  Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. , 1982, Journal of medicinal chemistry.

[34]  F. Garbagnati,et al.  Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI‐007) , 2001, Cancer.

[35]  R. Straubinger,et al.  Pharmacokinetics of paclitaxel-containing liposomes in rats , 2003, AAPS PharmSci.

[36]  C. C. Coffin,et al.  Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood , 1995, Infection and immunity.

[37]  J. O'flaherty,et al.  Differential Effects of Delivery of Omega-3 Fatty Acids to Human Cancer Cells by Low-Density Lipoproteins versus Albumin , 2004, Clinical Cancer Research.

[38]  D. Maria,et al.  Evaluation in melanoma‐bearing mice of an etoposide derivative associated to a cholesterol‐rich nanoemulsion , 2006, The Journal of pharmacy and pharmacology.

[39]  B. Lundberg,et al.  Preparation of biologically active analogs of serum low density lipoprotein. , 1984, Journal of lipid research.

[40]  D. Lu,et al.  Safety and utilization of blood components as therapeutic delivery systems. , 2003, Current pharmaceutical biotechnology.

[41]  D. Gospodarowicz,et al.  High-density lipoproteins and the proliferation of human tumor cells maintained on extracellular matrix-coated dishes and exposed to defined medium. , 1982, Cancer research.

[42]  D. Kingston,et al.  Synthesis and bioactivity of 2,4-diacyl analogues of paclitaxel. , 2001, Bioorganic & medicinal chemistry.

[43]  M. Brown,et al.  Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. , 1978, Blood.

[44]  T. Forte,et al.  Plasma lipoproteins in familial lecithin: cholesterol acyltransferase deficiency: structure of low and high density lipoproteins as revealed by elctron microscopy. , 1971, The Journal of clinical investigation.

[45]  R. Havel,et al.  Discoidal bilayer structure of nascent high density lipoproteins from perfused rat liver. , 1976, The Journal of clinical investigation.

[46]  Shaw Jm,et al.  Key issues in the delivery of pharmacological agents using lipoproteins: design of a synthetic apoprotein-lipid carrier. , 1991 .

[47]  S. Vitols,et al.  Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. , 1986, Cancer research.

[48]  M. Hammel,et al.  Structural characterisation of nucleoside loaded low density lipoprotein as a main criterion for the applicability as drug delivery system. , 2003, Chemistry and physics of lipids.

[49]  T. Abribat,et al.  The rise and rise of drug delivery , 2005, Nature Reviews Drug Discovery.

[50]  Luhua Lai,et al.  A New Atom-Additive Method for Calculating Partition Coefficients , 1997, J. Chem. Inf. Comput. Sci..

[51]  P. Linsel-Nitschke,et al.  HDL as a target in the treatment of atherosclerotic cardiovascular disease , 2005, Nature Reviews Drug Discovery.

[52]  D. Sparks,et al.  The charge and structural stability of apolipoprotein A-I in discoidal and spherical recombinant high density lipoprotein particles. , 1992, The Journal of biological chemistry.

[53]  S. Vitols,et al.  Selective uptake of a toxic lipophilic anthracycline derivative by the low-density lipoprotein receptor pathway in cultured fibroblasts. , 1985, Journal of medicinal chemistry.

[54]  M. Ala-Korpela,et al.  Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. , 2000, Biochimica et biophysica acta.

[55]  G. Gahrton,et al.  Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. , 1984, Blood.

[56]  T. Ishida,et al.  A Mutant High-Density Lipoprotein Receptor Inhibits Proliferation of Human Breast Cancer Cells , 2004, Cancer Research.

[57]  I. Papassotiriou,et al.  Serum Lipid Alterations in Acute Lymphoblastic Leukemia of Childhood , 2004, Journal of pediatric hematology/oncology.

[58]  E. Blakely,et al.  Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. , 2006, International journal of pharmaceutics.

[59]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[60]  R. Maranhão,et al.  Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers , 2006, Cancer Chemotherapy and Pharmacology.

[61]  M. Krieger,et al.  Reconstituted low density lipoprotein: a vehicle for the delivery of hydrophobic fluorescent probes to cells. , 1979, Journal of supramolecular structure.

[62]  H. Saragovi,et al.  Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. , 2001, Cancer research.

[63]  G. Paumgartner,et al.  Decreased High-Density Lipoprotein Cholesterol and Increased Low-Density Cholesterol Levels in Patients with Colorectal Adenomas , 1993, Annals of Internal Medicine.

[64]  M. Pieters,et al.  Development of lipoprotein-like lipid particles for drug targeting: neo-high density lipoproteins. , 1993, Molecular pharmacology.

[65]  S. Swain,et al.  Emerging drugs to replace current leaders in first-line therapy for breast cancer , 2006, Expert opinion on emerging drugs.

[66]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[67]  D. Fernandes,et al.  Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies , 2005, Cancer Chemotherapy and Pharmacology.

[68]  P. Barter,et al.  Hugh sinclair lecture: the regulation and remodelling of HDL by plasma factors. , 2002, Atherosclerosis. Supplements.

[69]  G. Favre,et al.  High density lipoprotein3 binding sites are related to DNA biosynthesis in the adenocarcinoma cell line A549. , 1993, Journal of lipid research.

[70]  N. Fidge.  High density lipoprotein receptors, binding proteins, and ligands. , 1999, Journal of lipid research.

[71]  Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins. , 2000, European journal of medicinal chemistry.

[72]  J. Faye,et al.  Interaction of estradiol and high density lipoproteins on proliferation of the human breast cancer cell line MCF-7 adapted to grow in serum free conditions. , 1985, Biochemical and biophysical research communications.

[73]  G. Gahrton,et al.  Lipoprotein receptors in acute myelogenous leukemia: failure to detect increased low-density lipoprotein (LDL) receptor numbers in cell membranes despite increased cellular LDL degradation. , 1998, The American journal of pathology.

[74]  G. Baillie,et al.  A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro. , 2002, Journal of lipid research.

[75]  M. Hayden,et al.  Restoration of Endothelial Function by Increasing High‐Density Lipoprotein in Subjects With Isolated Low High‐Density Lipoprotein , 2003, Circulation.

[76]  G. Baillie,et al.  Physicochemical properties of microemulsion analogues of low density lipoprotein containing amphiphatic apoprotein B receptor sequences. , 2001, International journal of pharmaceutics.

[77]  D. Pc,et al.  LDL-mediated drug targeting. , 1990 .

[78]  K. Fung,et al.  Circumvention of multidrug resistance and reduction of cardiotoxicity of doxorubicin in vivo by coupling it with low density lipoprotein. , 2002, Life sciences.

[79]  P. Low,et al.  Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics. , 2002, Bioorganic & medicinal chemistry.

[80]  Patrick Soon-Shiong,et al.  Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  Bin Lou,et al.  High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. , 2005, World journal of gastroenterology.

[82]  M. Oda,et al.  Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B Published, JLR Papers in Press, November 28, 2005. , 2006, Journal of Lipid Research.

[83]  P. Lerch,et al.  Production and Characterization ofa Reconstituted High Density Lipoprotein for Therapeutic Applications , 1996, Vox sanguinis.

[84]  E. Simpson,et al.  Cholesterol metabolism in cancer cells in monolayer culture. III. Low‐density lipoprotein metabolism , 1981, International journal of cancer.

[85]  S. Vitols,et al.  Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: studies in human leukemic cells. , 2006, Leukemia research.

[86]  J. Gmiński,et al.  Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. , 2000, International journal of molecular medicine.

[87]  X. Geng,et al.  Tumor-specific novel taxoid-monoclonal antibody conjugates. , 2004, Journal of medicinal chemistry.

[88]  Alan Pater,et al.  Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[89]  R. Hovorka,et al.  Effects of intravenous infusion of lipid-free apo A-I in humans. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[90]  A. Safavy,et al.  Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. , 2003, Bioconjugate chemistry.

[91]  R. Clayman,et al.  Low density lipoprotein‐receptor activity is lost in vivo in malignantly transformed renal tissue , 1986, FEBS letters.

[92]  S. Vitols,et al.  Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. , 2002, Biochemical pharmacology.

[93]  T. V. van Berkel,et al.  Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes. , 1998, British Journal of Cancer.

[94]  T C Yih,et al.  Engineered nanoparticles as precise drug delivery systems , 2006, Journal of cellular biochemistry.

[95]  D. Aggarwal,et al.  Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.

[96]  G. Desoye,et al.  Trophoblast-like human choriocarcinoma cells serve as a suitable in vitro model for selective cholesteryl ester uptake from high density lipoproteins. , 2003, European journal of biochemistry.

[97]  H. Kuriyama,et al.  Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs. , 2002, Biological & pharmaceutical bulletin.

[98]  Hui Li,et al.  Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[99]  M. Hirata,et al.  Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein , 1993, Lipids.

[100]  A. Hammer,et al.  Scavenger receptor class B, type I on non-malignant and malignant human epithelial cells mediates cholesteryl ester-uptake from high density lipoproteins. , 2003, The international journal of biochemistry & cell biology.

[101]  R. Zhou,et al.  MR and fluorescent imaging of low-density lipoprotein receptors. , 2004, Academic radiology.

[102]  E. Reddi,et al.  The role of lipoproteins in the delivery of tumour-targeting photosensitizers. , 1993, The International journal of biochemistry.

[103]  T. V. van Berkel,et al.  Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. , 1994, Biochemistry.

[104]  K. Fung,et al.  Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. , 2001, Life sciences.

[105]  F. Ruschitzka,et al.  High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men , 2002, Circulation.

[106]  A. Branchi,et al.  Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects , 2000, International journal of clinical & laboratory research.

[107]  B Lundberg,et al.  Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. , 1987, Cancer research.

[108]  P. Pani,et al.  Total and HDL cholesterol in human hematologic neoplasms. , 1991, International journal of hematology.

[109]  S. Broitman,et al.  Evidence for deficiency of low density lipoprotein receptor on human colonic carcinoma cell lines. , 1990, Cancer research.

[110]  B. Allison,et al.  Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. , 1994, British Journal of Cancer.

[111]  H. W. Scheeren,et al.  Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin. , 2000, Journal of medicinal chemistry.

[112]  T. V. van Berkel,et al.  Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. , 2001, Advanced drug delivery reviews.